Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel
Status:
Completed
Trial end date:
2021-07-11
Target enrollment:
Participant gender:
Summary
Healthcare workers are particularly at risk of SARS-CoV-2. This study aims to assess the
efficacy of a daily single dose of tenofovir disoproxil fumarate (TDF) (245 mg)/
Emtricitabine (FTC) (200 mg), a daily single dose of hydroxychloroquine (HC) (200 mg), a
daily single dose of TDF (245 mg)/FTC (200 mg) plus HC (200 mg) versus placebo, during 12
weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing clinical
severity COVID-19 among hospital healthcare workers aged 18 to 70 years in public and private
hospitals in Spain.
Phase:
Phase 3
Details
Lead Sponsor:
Plan Nacional sobre el Sida (PNS)
Collaborator:
Effice Servicios Para la Investigacion S.L.
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Hydroxychloroquine Tenofovir